214
Participants
Start Date
January 31, 2012
Primary Completion Date
October 31, 2013
Study Completion Date
November 30, 2013
lesinurad
Tablets, 400 mg QD
Placebo
Tablets, Placebo QD
Auckland
Auckland
Anderlecht
Tauranga
Genk
Butterfield
Durban
Yvoir
Gozée
Hobart
Tasmania
Stellenbosch
Rondebosch
Kortrijk
New York
Hartsdale
Brooklyn
New Windsor
Pittsburgh
Lancaster
Sellersville
Jenkintown
Lansdale
Reading
Richmond
Chesapeake
Suffolk
Morgantown
Winston-Salem
Raleigh
Hickory
Spartanburg
Myrtle Beach
Rock Hill
Newnan
Port Orange
Jacksonville
Miami
Miami
Boynton Beach
Plant City
Tampa
Winter Haven
Birmingham
Birmingham
Brentwood
Spring Hill
Olive Branch
Jackson
Louisville
Lexington
Elizabethtown
Perrysburg
Middleburg Heights
Willoughby Hills
Cincinnati
Cincinnati
Southfield
South Traverse
Fargo
Chicago
Washington
Metairie
Little Rock
Jonesboro
Norman
Dallas
Houston
Victoria
San Antonio
Englewood
Denver
Denver
Colorado Springs
Meridian
South Bountiful
West Layton
West Jordon
Phoenix
Glendale
Tucson
Albuquerque
Albuquerque
Huntington Park
Covina
Irvine
Anaheim
Carmichael
Honolulu
Seattle
Spokane
Milford
Trumbull
Coquitiam
Coquitlam
Victoria
London
Mississauga
Toronto
Québec
Rimouski
Dresden
Leipzig
Dresden
Pretoria
Thabazimbi
Lead Sponsor
Ardea Biosciences, Inc.
INDUSTRY